In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Editorial Advisory Board
Ask The Analyst
Partnered Content
PDF Library
RSS Feeds
Subscribe
Advertising
Guidelines for Contributors
Report Store
UsernamePublicRestriction

Heidelberg Pharma AG

www.heidelberg-pharma.com

Latest From Heidelberg Pharma AG

Bookmark
  • News

Appointments: New CEO For Silence Therapeutics, Medical Heads Join Merck, Breath Therapeutics, Immusoft

By Jo Shorthouse

David Solomon’s entrance as Silence Therapeutics’ new CEO leads this week’s new hires. While Ireland-based Malin shakes up its board of directors, other execs join Merck, Apeiron Biologics, Vectura, Roivant, OncoSec, Breath Therapeutics, Immusoft and M3 Biotechnology.

Appointments BioPharmaceutical
Bookmark
  • Analysis

Start-Up Quarterly Statistics: Early Funding Declined, But Deal Dollars Flowed

By Deanna Kamienski

A review of biopharma startup dealmaking and financing activity from January through March 2017, based on data from Strategic Transactions, showed a 19% decline in startup financing compared with the fourth quarter of 2016, but big pharmas provided capital in the form of alliance fees.

StartUps and SMEs Financing
Bookmark
  • News

Deal Watch: Genentech Pays Big For Seragon’s Early Assets

By Lisa LaMotta

Genentech pays $725 million upfront for San Diego oncology firm Seragon, and Bluebird adds gene-editing and cell-signaling capabilities by acquiring Precision Genomic Engineering. It was a deal-heavy week ahead of the July 4th Holiday.

BioPharmaceutical Deals
Bookmark
  • News

BioNotebook: PaxVax, Bluebird/Pregenen, RedHill/Wilex, CureVac/Sanofi Pasteur, Synchroneuron, Advanced Cell, Raptor, Ablynx

By Mandy Jackson

PaxVax has 1st Phase III success; Bluebird buys Pregenen; RedHill acquires Wilex asset; Sanofi options CureVac vaccine; Synchroneuron gets VC funding; and Advanced Cell, Raptor, Ablynx raise new cash.

Gastrointestinal Infectious Diseases
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
    • Radiopharmaceuticals, Contrast Agents
  • Therapeutic Areas
  • Cancer
  • Alias(es)
  • Wilex Biotechnology GMBH
  • Wilex AG
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Germany
  • Parent & Subsidiaries
  • Heidelberg Pharma AG
  • Senior Management
  • Jan Schmidt-Brand, PhD, CEO & CFO
    Andreas Pahl, Head, R&D
  • Contact Info
  • Heidelberg Pharma AG
    Phone: (49) 6203 1009 0
    Schriesheimer Str. 101
    Ladenburg, D-68526
    Germany
UsernamePublicRestriction

Register

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By